Cole Baker

Cole Baker

Auto-generated profile, based on publicly available information

Cole Baker

1910

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
CBCole Baker
Cole Baker
FBFrancis A. Biotech
Francis A. Biotech
LCLakshmi G. Chivukula
Lakshmi G. Chivukula
LWLiping Wu
Liping Wu
LPLaurence Philippe-Venec
Laurence Philippe-Venec
JAJennifer O. Asher
Jennifer O. Asher
Cyclic peptides are a promising class of therapeutics that have the potential for oral bioavailability but are hindered by cell membrane permeability and aqueous solubility. Artificial intelligence (AI) can address the challenging multiparameter optimization of cyclic peptides, but it relies on wet lab ground truth biological data that are scarce, sparse, and dominated by hydrophobic amino acids. Here, we introduce PEGASUS, a multimodal AI model that achieves state-of-the-art performance in predicting cell membrane permeability. PEGASUS integrates an innovative high-throughput proxy biological assay (1910 PPA), which generates billions of cyclic peptides separated by permeability-related characteristics with solvent-dependent computational simulations. PEGASUS informs rules for designing cell-permeable cyclic peptides with high aqueous solubility that resemble FDA-approved therapeutics based on polarity and charge. Combining these rules with a novel generative AI, we design the first published cyclic peptides with more than two polar or ionizable fragments to achieve in vitro cell membrane permeability.